It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Muscle invasive bladder cancer (MIBC) is a molecularly diverse disease with varied clinical outcomes. Molecular studies typically employ bulk sequencing analysis, giving a transcriptomic snapshot of a section of the tumour. However, tumour tissues are not homogeneous, but are composed of distinct compartments such as the tumour and stroma. To investigate the molecular profiles of bladder cancer, whilst also maintaining the spatial complexity of the tumours, we employed whole transcriptome Digital Spatial Profiling (DSP). With this method we generated a dataset of transcriptomic profiles of tumour epithelium, stroma, and immune infiltrate. With these data we investigate the spatial relationship of molecular subtype signatures and ligand signalling events. We find that Basal/Squamous and Classical subtypes are mostly restricted to tumour regions, while the stroma-rich subtype signatures are abundant within the stroma itself. Additionally, we identify ligand signalling events occurring between tumour, stroma, and immune infiltrate regions, such as immune infiltrate derived GPNMB, which was highly correlated with VEGFA expression within the tumour. These findings give us new insights into the diversity of MIBC at a molecular level and provide a dataset with detailed spatial information that was not available before in bladder cancer research.
A spatial transcriptomics study in bladder cancer investigates the spatial localization of molecular subtype signatures and ligand signaling events.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Medicines Discovery Catapult, Cheshire, UK (GRID:grid.500485.c) (ISNI:0000 0004 7699 9615)
2 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407)
3 CRUK Manchester Centre, Manchester, UK (GRID:grid.500485.c) (ISNI:0000 0004 0612 4047)
4 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407); Mount Vernon Centre for Cancer Treatment, Northwood, UK (GRID:grid.477623.3) (ISNI:0000 0004 0400 1422)
5 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407); The Christie NHS Foundation Trust, Manchester, UK (GRID:grid.412917.8) (ISNI:0000 0004 0430 9259)